Bibliometric Analysis of METTL3: Current Perspectives, Highlights, and Trending Topics

Overview

Journal Open Life Sci

Specialty Biology

Date 2023 Mar 27

PMID 36970605

Authors

Hanqi Liu

Yanqing Huang

Shanshan Lu

Didi Yuan

Junwen Liu

Affiliations

Soon will be listed here.

Abstract

N6-methyladenosine (mA) is a representative of RNA methylation modification, which plays a critical role in the epigenetic modification process of regulating human diseases. As a key protein for mA, methyltransferase 3 (METTL3) had been identified to be associated with a variety of diseases. The publications related to METTL3 were searched in the Web of Science Core Collection from the earliest mention to July 1st, 2022. Being screened by the retrieval strategy, a total of 1,738 articles related to METTL3 were retrieved. Much of our work focused on collecting the data of annual publication outputs, high-yielding countries/regions/authors, keywords, citations, and journals frequently published for qualitative and quantitative analysis. We found that diseases with high correlations to METTL3 not only included various known cancers but also obesity and atherosclerosis. In addition to mA-related enzyme molecules, the most frequent key molecules were MYC proto-oncogene (C-MYC), Enhancer of zeste homolog 2 (EZH2), and Phosphatase and tensin homolog deleted on chromosome 10 (PTEN). METTL3 and methyltransferase 14 (METTL14) may function through opposite regulatory pathways in the same disease. "Leukemia," "Liver Cancer," and "Glioblastoma" were speculated to be potential hotspots in METTL3 related study. The number of publications had significantly surged year by year, demonstrating the growing importance of the research on epigenetic modification in the pathology of various diseases.

Citing Articles

Recent advances in noncoding RNA modifications of gastrointestinal cancer.

Hara T, Meng S, Arao Y, Saito Y, Inoue K, Rennie S Cancer Sci. 2024; 116(1):8-20.

PMID: 39487589 PMC: 11711047. DOI: 10.1111/cas.16380.

Regulatory Network of Methyltransferase-Like 3 in Stem Cells: Mechanisms and Medical Implications.

Zeng Y, Wang F, Li S, Song B Cell Transplant. 2024; 33:9636897241282792.

PMID: 39466679 PMC: 11528761. DOI: 10.1177/09636897241282792.

Association between methyltransferase-like 3 and non-small cell lung cancer: pathogenesis, therapeutic resistance, and clinical applications.

Su X, Feng Y, Qu Y, Mu D Transl Lung Cancer Res. 2024; 13(5):1121-1136.

PMID: 38854947 PMC: 11157379. DOI: 10.21037/tlcr-24-85.

References

Zhang B, Han L, Tang Y, Zhang G, Fan X, Zhang J . METTL14 regulates M6A methylation-modified primary miR-19a to promote cardiovascular endothelial cell proliferation and invasion. Eur Rev Med Pharmacol Sci. 2020; 24(12):7015-7023. DOI: 10.26355/eurrev_202006_21694. View

Duan R, Du W, Guo W . EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020; 13(1):104. PMC: 7385862. DOI: 10.1186/s13045-020-00937-8. View

Shi J, Zhang P, Dong X, Yuan J, Li Y, Li S . METTL3 knockdown promotes temozolomide sensitivity of glioma stem cells via decreasing MGMT and APNG mRNA stability. Cell Death Discov. 2023; 9(1):22. PMC: 9868123. DOI: 10.1038/s41420-023-01327-y. View

Cooper I . Bibliometrics basics. J Med Libr Assoc. 2015; 103(4):217-8. PMC: 4613387. DOI: 10.3163/1536-5050.103.4.013. View

Chen M, Wei L, Law C, Tsang F, Shen J, Cheng C . RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2017; 67(6):2254-2270. DOI: 10.1002/hep.29683. View

Wu H, Li F, Zhu R . miR-338-5p inhibits cell growth and migration via inhibition of the METTL3/m6A/c-Myc pathway in lung cancer. Acta Biochim Biophys Sin (Shanghai). 2020; 53(3):304-316. DOI: 10.1093/abbs/gmaa170. View

Pan F, Lin X, Hao L, Chu X, Wan H, Wang R . The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives. Front Cell Dev Biol. 2021; 9:674919. PMC: 8144501. DOI: 10.3389/fcell.2021.674919. View

Tang J, Huang M, Peng H, He J, Gong L, Yang M . METTL3-mediated Hsa_circ_0000390 downregulation enhances the proliferation, migration, and invasion of colorectal cancer cells by increasing Notch1 expression. Hum Cell. 2023; 36(2):703-711. DOI: 10.1007/s13577-022-00835-w. View

Zhao W, Cui Y, Liu L, Ma X, Qi X, Wang Y . METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated mA Modification. Mol Ther Nucleic Acids. 2020; 20:1-12. PMC: 7057159. DOI: 10.1016/j.omtn.2020.01.033. View

10.

Bi X, Lv X, Liu D, Guo H, Yao G, Wang L . METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway. Cancer Gene Ther. 2020; 28(3-4):335-349. DOI: 10.1038/s41417-020-00222-3. View

11.

Ma J, Yang F, Zhou C, Liu F, Yuan J, Wang F . METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N -methyladenosine-dependent primary MicroRNA processing. Hepatology. 2016; 65(2):529-543. DOI: 10.1002/hep.28885. View

12.

Stephan P, Veugelers R, Wang J . Reviewers are blinkered by bibliometrics. Nature. 2017; 544(7651):411-412. DOI: 10.1038/544411a. View

13.

Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

14.

Pan T . N6-methyl-adenosine modification in messenger and long non-coding RNA. Trends Biochem Sci. 2013; 38(4):204-9. PMC: 3608796. DOI: 10.1016/j.tibs.2012.12.006. View

15.

Liu B, Tu Y, Ni G, Yan J, Yue L, Li Z . Total Flavones of Ameliorates Podocyte Pyroptosis and Injury in High Glucose Conditions by Targeting METTL3-Dependent mA Modification-Mediated NLRP3-Inflammasome Activation and PTEN/PI3K/Akt Signaling. Front Pharmacol. 2021; 12:667644. PMC: 8319635. DOI: 10.3389/fphar.2021.667644. View

16.

Chen W, Qi J, Hang Y, Wu J, Zhou X, Chen J . Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA. Eur Rev Med Pharmacol Sci. 2020; 24(8):4263-4270. DOI: 10.26355/eurrev_202004_21006. View

17.

Lu Y, Wang X, Li Z, Wu A, Cheng W . Hsa_circ_0001658 accelerates the progression of colorectal cancer through miR-590-5p/METTL3 regulatory axis. World J Gastrointest Oncol. 2023; 15(1):76-89. PMC: 9850756. DOI: 10.4251/wjgo.v15.i1.76. View

18.

Qin Y, Qiao Y, Li L, Luo E, Wang D, Yao Y . The mA methyltransferase METTL3 promotes hypoxic pulmonary arterial hypertension. Life Sci. 2021; 274:119366. DOI: 10.1016/j.lfs.2021.119366. View

19.

Li J, Yao H, Huang J, Li C, Zhang Y, Xu R . METTL3 promotes prostatic hyperplasia by regulating PTEN expression in an mA-YTHDF2-dependent manner. Cell Death Dis. 2022; 13(8):723. PMC: 9391461. DOI: 10.1038/s41419-022-05162-4. View

20.

Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M . The mA methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene. 2019; 38(19):3667-3680. DOI: 10.1038/s41388-019-0683-z. View